We are live on ! Find out more
TARA icon

Protara Therapeutics
TARA

25 hedge funds and large institutions have $17.5M invested in Protara Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

39% more capital invested

Capital invested by funds: $12.6M → $17.5M (+$4.89M)

25% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 4

0.07% more ownership

Funds ownership: 1.18% → 1.25% (+0.07%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less funds holding

Funds holding: 28 → 25 (-3)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

Holders
25
Holders Change
-3
Holders Change %
-10.71%
% of All Funds
0.62%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.1%
New
3
Increased
5
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
PI
Pharmstandard International
Luxembourg
+$719K
2
Renaissance Technologies
Renaissance Technologies
New York
+$68.3K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$26.5K
4
VF
Virtu Financial
New York
+$16.8K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.8K

Top Sellers

1
BCM
Bridgeway Capital Management
Texas
-$73K
2
WS
Wedbush Securities
California
-$25.9K
3
TRCT
Tower Research Capital (TRC)
New York
-$4K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$3.72K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.12K
Name Holding Trade Value Shares
Change 		Change in
Stake
A
1
Abingworth
United Kingdom
$3.94M – – –
PI
2
Pharmstandard International
Luxembourg
$3.34M +$719K +12,564 +43%
RCM
3
RA Capital Management
Massachusetts
$2.67M – – –
DM
4
Deerfield Management
New York
$2.45M – – –
MAM
5
MPM Asset Management
Massachusetts
$1.97M – – –
PA
6
Perceptive Advisors
New York
$668K – – –
DVC
7
Deer VII & Co
New York
$630K – – –
BBA
8
Baker Bros. Advisors
New York
$597K – – –
Vanguard Group
9
Vanguard Group
Pennsylvania
$417K +$12.8K +223 +4%
Renaissance Technologies
10
Renaissance Technologies
New York
$344K +$68.3K +1,193 +38%
FCI
11
Financial Counselors Inc
Kansas
$100K – – –
WS
12
Wedbush Securities
California
$71K -$25.9K -453 -34%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$69K – – –
KCM
14
Kornitzer Capital Management
Kansas
$50K – – –
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$37K +$26.5K +464 New
RJFSA
16
Raymond James Financial Services Advisors
Florida
$33K – – –
ARTA
17
A.R.T. Advisors
New York
$33K +$458 +8 +2%
Northern Trust
18
Northern Trust
Illinois
$28K -$114 -2 -0.6%
VF
19
Virtu Financial
New York
$23K +$16.8K +293 New
Mariner
20
Mariner
Kansas
$20K – – –
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$14K -$2.12K -37 -17%
LWCFA
22
Loring Wolcott & Coolidge Fiduciary Advisors
Massachusetts
$13K +$9.04K +158 New
BlackRock
23
BlackRock
New York
$10K +$572 +10 +9%
Royal Bank of Canada
24
Royal Bank of Canada
Ontario, Canada
$7K -$3.72K -65 -44%
BCM
25
Bridgeway Capital Management
Texas
– -$73K -1,180 Closed
1
2

TARA Hedge Fund Activity: Q3 2017 in Review

25 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q3 2017, worth a combined $17.5M — up 39% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of TARA and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 5 added.

The largest buyer was Pharmstandard International, adding an estimated $719K. The largest seller was Bridgeway Capital Management, exiting entirely with an estimated $73K sold.

  • 25 institutional investors held Protara Therapeutics (TARA) as of Q3 2017, down from 28 in Q2 2017.
  • Funds reported $17.5M of Protara Therapeutics stock for Q3 2017, up 39% quarter-over-quarter.
  • 3 funds opened new Protara Therapeutics positions in Q3 2017 and 5 closed out, a net change of -2 holders.
  • The largest Protara Therapeutics buyer in Q3 2017 was Pharmstandard International, an estimated $719K added.
  • The largest Protara Therapeutics seller in Q3 2017 was Bridgeway Capital Management, an estimated $73K sold.

Based on aggregated 13F filings for Q3 2017.